The use of oral bisphosphonates was not found to be significantly associated with incident esophageal or gastric cancer, according to a retrospective analysis of patients from the UK General Practice Research Database. Based on their findings, Cardwell and colleagues concluded that, for patients in which they are clinically indicated, bisphosphonates should not be withheld solely on the basis of possible esophageal cancer risk.
